SRPT · XBRL financial data

Sarepta Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (SRPT's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	332	397*	413	363	467	658	745	611	399	443	731	401
Revenue from contracts with customers	309	365*	359	361	430	638*	612	513	370	370*	331	329
Cost of revenue	—	—	—	—	—	—	—	—	—	year only	—	—
Gross profit	—	—	309	316	338	506	474	361	219	(29)	—	—
Selling, general and administrative	121	132*	127	139	128	164*	134	138	92	128*	109	108
Operating income (loss)	(21)	25*	35	(1)	22	162*	(300)	116	(103)	(412)*	358	13
Interest income	10	9*	7	8	8	8*	10	5	7	8*	6	6
Interest expense	5	5*	4	5	5	(32)*	(5)	5	8	(55)*	(22)	(22)
Other income (expense)	(12)	16*	7	14	12	10*	(83)	38	48	(22)*	(15)	(15)
Income tax expense (benefit)	8	(5)*	5	7	0	13*	64	(43)	(14)	5*	12	3
Net income (loss)	(41)	46*	36	6	34	159	(448)	197	(180)	(412)	331	(5)
Earnings per share, basic USD per share	(0.46)	—	0.38	0.07	0.35	1.65	(4.60)	2.01	(1.80)	(3.93)	3.15	(0.05)
Earnings per share, diluted USD per share	(0.46)	—	0.37	0.07	0.34	1.50	(4.60)	1.89	(1.80)	(3.93)	2.88	(0.05)
Weighted average shares, basic millions of shares	89	104*	94	95	95	96*	97	98	100	105*	105	105
Weighted average shares, diluted millions of shares	89	104*	99	99	100	133*	97	107	100	96*	122	105

Balance sheet

CSV

Fiscal quarters (SRPT's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	542	428	427	384	198	1,103	241	511	613	801	464	571
Short-term investments	1,192	1,248	963	1,077	1,001	252	282	290	238	138	189	217
Marketable securities	1,192	1,248	963	1,077	—	—	—	—	—	—	—	—
Marketable securities, non-current	—	428	—	—	—	—	—	—	—	—	—	—
Accounts receivable	319	400	379	360	435	602	659	527	396	398	395	377
Inventory	244	323	374	486	566	750	941	994	1,077	915	1,001	904
Total current assets	2,451	2,579	2,465	2,684	2,685	3,073	2,433	2,657	2,722	2,538	2,310	2,224
Property and equipment, net	212	227	249	276	306	340	361	372	359	345	336	326
Right-of-use asset	133	130	126	124	141	148	147	143	139	125	124	121
Total assets	3,110	3,265	3,224	3,424	3,600	3,963	3,465	3,680	3,493	3,350	3,179	3,189
Accounts payable	88	165	92	107	119	214	156	137	94	281	70	51
Accrued liabilities	322	315	283	350	345	374	392	377	296	360	302	325
Current portion of long-term debt	—	105	106	92	92	0	—	—	—	—	—	—
Total current liabilities	451	654	609	688	699	732	606	920	921	1,095	499	503
Lease liability, non-current	135	141	140	144	170	192	205	214	215	199	199	198
Total liabilities	2,345	2,405	2,263	2,347	2,379	2,435	2,323	2,322	2,173	2,209	1,674	1,661
Accumulated deficit	(4,492)	(4,446)	(4,410)	(4,404)	(4,370)	(4,211)	(4,658)	(4,462)	(4,642)	(4,877)	(4,546)	(4,551)
Total stockholders' equity	764	859	961	1,077	1,221	1,528	1,143	1,357	1,320	1,141	1,505	1,528
Total liabilities and equity	3,110	3,265	3,224	3,424	3,600	3,963	3,465	3,680	3,493	3,350	3,179	3,189
Common shares outstanding (cover page) millions of shares	94	94	95	95	96	97	98	98	105	105	106	106

Cash flows

CSV

Fiscal quarters (SRPT's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(41)	46*	36	6	34	159	(448)	197	(180)	(412)	331	(5)
Stock-based compensation	48*	46*	41	50*	43*	50*	41	37*	15*	30*	29	24*
Depreciation and amortization	11*	11*	9	9*	10*	10*	10	11*	18*	5*	11	10*
Net cash from operating activities	(115)*	(55)*	(242)	15*	(71)*	92*	(583)	261*	(15)*	131*	(203)	197*
Purchases of property and equipment	30*	19*	32	29*	37*	38*	44	32*	23*	4*	2	1*
Net cash from investing activities	(211)*	(64)*	219	(99)*	(129)*	764*	(291)	32*	232*	96*	(134)	(93)*
Proceeds from issuing common stock	—	year only	—	—	—	0*	—	—	—	0*	—	—
Share repurchases	—	year only	—	—	0*	0*	—	—	0*	0*	—	—
Net cash from financing activities	15*	2*	22	40*	14*	49*	12	(24)*	(118)*	(39)*	0	0*
Net change in cash	(310)*	(117)*	(1)	(44)*	(186)*	905*	(862)	270*	100*	188*	(337)	104*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Sarepta Therapeutics	571	401	197*	105.6M	—	Q2 FY26 10-QJun 30, 2026
Supernus Pharmaceuticals	176	227	6.6*	58.2M	—	Q3 FY26 10-QSep 30, 2026
Ocular Therapeutix	599	13	(67)*	219.6M	8.9 quarters	Q2 FY26 10-QJun 30, 2026
Ligand Pharmaceuticals	56	79	(28)*	20.0M	—	Q3 FY26 10-QSep 30, 2026
Amicus Therapeutics	214	185*	16*	314.0M	—	Q4 FY25 10-KDec 31, 2025
Apellis Pharmaceuticals	405	268	(61)	128.0M	6.6 quarters	Q1 FY26 10-QMar 31, 2026
Indivior Pharmaceuticals	305	356	97*	118.0M	—	Q3 FY26 10-QSep 30, 2026
Biocryst Pharmaceuticals	155	not reported	104*	255.5M	—	Q2 FY26 10-QJun 30, 2026
Agios Pharmaceuticals	100	45	(57)*	59.7M	10.8 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.